What is Rockwell Med Inc's earnings per share (EPS)?

Rockwell Med Inc (RMTI) reported diluted earnings per share of $-0.15 for fiscal year 2025. This represents a -400.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rockwell Med Inc Financials

RMTI

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Rockwell Med Inc (RMTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RMTI FY2025 2026-05-07

A margin-recovery story became a volume shortfall problem, with fixed costs overwhelming sales even as liquidity stayed intact.

From FY2024 to FY2025, revenue fell 31.8% while gross margin held near 17%, which points to weaker volume rather than a collapse in unit economics. The more telling shift was below gross profit: operating margin moved from 0.6% to -6.8%, showing that overhead coverage broke when sales shrank.

The cash drain was much smaller than the accounting loss: net income was -$5.3M but operating cash flow was only -$659K. That gap implies working-capital release softened the hit, so FY2025 looked worse on the income statement than it did in near-term cash consumption.

The balance sheet now looks liquid and less debt-dependent, with a current ratio of 4.0x and debt-to-equity of 0.2x, after liabilities were cut over the last two years. But liquidity was not built only from operations: financing cash flow added $4.3M in FY2025 while the share count rose, so part of the cushion came from external capital.

Financial Health Signals

Financial Health Score 53/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Rockwell Med Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-7.67

Rockwell Med Inc scores -7.67, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($22.2M) relative to total liabilities ($20.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

2/9

Rockwell Med Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.12x

For every $1 of reported earnings, Rockwell Med Inc generates $0.12 in operating cash flow (-$659K OCF vs -$5.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4.2x

Rockwell Med Inc earns $-4.2 in operating income for every $1 of interest expense (-$4.7M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$69.3M

YoY-31.8%

5Y CAGR+2.2%

10Y CAGR+2.3%

Rockwell Med Inc generated $69.3M in revenue in fiscal year 2025. This represents a decrease of 31.8% from the prior year.

EBITDA

-$2.5M

YoY-189.6%

Rockwell Med Inc's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 189.6% from the prior year.

Net Income

-$5.3M

YoY-1007.1%

Rockwell Med Inc reported -$5.3M in net income in fiscal year 2025. This represents a decrease of 1007.1% from the prior year.

EPS (Diluted)

$-0.15

YoY-400.0%

Rockwell Med Inc earned $-0.15 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 400.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.2M

YoY-137.6%

Rockwell Med Inc generated -$1.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 137.6% from the prior year.

Cash & Debt

$10.7M

YoY-31.6%

5Y CAGR-26.1%

10Y CAGR-10.1%

Rockwell Med Inc held $10.7M in cash against $8.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

39M

YoY+15.7%

Rockwell Med Inc had 39M shares outstanding in fiscal year 2025. This represents an increase of 15.7% from the prior year.

Margins & Returns

Gross Margin

16.9%

YoY-0.3pp

5Y CAGR+12.5pp

10Y CAGR+0.7pp

Rockwell Med Inc's gross margin was 16.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin

-6.8%

YoY-7.4pp

5Y CAGR+38.9pp

10Y CAGR+20.5pp

Rockwell Med Inc's operating margin was -6.8% in fiscal year 2025, reflecting core business profitability. This is down 7.4 percentage points from the prior year.

Net Margin

-7.7%

YoY-7.2pp

5Y CAGR+42.0pp

10Y CAGR+18.4pp

Rockwell Med Inc's net profit margin was -7.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.2 percentage points from the prior year.

Return on Equity

-14.4%

YoY-12.9pp

5Y CAGR+76.0pp

10Y CAGR+8.8pp

Rockwell Med Inc's ROE was -14.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.9 percentage points from the prior year.

Capital Allocation

R&D Spending

YoY-100.0%

Rockwell Med Inc invested $0 in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$542K

YoY-46.4%

Rockwell Med Inc invested $542K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 46.4% from the prior year.

RMTI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$69.3M-31.8%	$101.5M+21.4%	$83.6M+14.8%	$72.8M+17.6%	$61.9M-0.4%	$62.2M
Cost of Revenue	$57.6M-31.5%	$84.0M+12.1%	$74.9M+9.0%	$68.7M+6.8%	$64.4M+8.2%	$59.5M
Gross Profit	$11.7M-33.1%	$17.5M+100.9%	$8.7M+113.5%	$4.1M+268.5%	-$2.4M-188.8%	$2.7M
R&D Expenses	$0-100.0%	$19K-98.3%	$1.1M-64.5%	$3.1M-54.4%	$6.8M-3.6%	$7.1M
SG&A Expenses	$14.0M-0.5%	$14.1M+16.2%	$12.1M-22.4%	$15.6M+1.9%	$15.3M-5.2%	$16.2M
Operating Income	-$4.7M-871.5%	$608K+109.1%	-$6.7M+60.3%	-$16.8M+44.7%	-$30.3M-6.7%	-$28.4M
Interest Expense	$1.1M-10.4%	$1.3M-45.5%	$2.3M+18.9%	$1.9M-18.0%	$2.4M+25.6%	$1.9M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$5.3M-1007.1%	-$480K+94.3%	-$8.4M+54.8%	-$18.7M+42.8%	-$32.7M-5.8%	-$30.9M
EPS (Diluted)	$-0.15-400.0%	$-0.03+91.9%	$-0.37+71.8%	$-1.31+65.8%	$-3.83	$-0.41

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$17.3M-5.5%	$18.3M+15.2%	$15.9M-0.9%	$16.1M-15.0%	$18.9M-23.3%	$24.7M-12.9%	$28.3M+9.6%	$25.8M
Cost of Revenue	$14.4M-0.2%	$14.5M+6.0%	$13.7M+0.6%	$13.6M-14.5%	$15.9M-24.5%	$21.0M-4.7%	$22.1M+3.7%	$21.3M
Gross Profit	$2.9M-25.3%	$3.9M+70.7%	$2.3M-9.2%	$2.5M-17.7%	$3.0M-16.2%	$3.6M-41.8%	$6.2M+37.1%	$4.5M
R&D Expenses	N/A	$0	$0	$0	$0-100.0%	$1K	$0	$0
SG&A Expenses	$3.8M+2.0%	$3.7M+12.4%	$3.3M+1.4%	$3.3M-11.1%	$3.7M+11.6%	$3.3M-7.6%	$3.6M+3.7%	$3.4M
Operating Income	-$1.5M-271.9%	-$398K+74.9%	-$1.6M-17.4%	-$1.3M+0.8%	-$1.4M-162.0%	-$519K-126.8%	$1.9M+275.9%	$515K
Interest Expense	$282K-1.4%	$286K+0.4%	$285K+3.3%	$276K-0.4%	$277K-4.2%	$289K-4.3%	$302K+30.2%	$232K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.6M-189.7%	-$554K+68.4%	-$1.8M-17.5%	-$1.5M+1.5%	-$1.5M-100.4%	-$756K-145.4%	$1.7M+385.1%	$343K
EPS (Diluted)	$-0.04	N/A	$-0.050.0%	$-0.05-25.0%	$-0.04	N/A	$0.04+300.0%	$0.01

RMTI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$57.1M-3.5%	$59.2M+13.5%	$52.2M+11.9%	$46.6M-4.0%	$48.6M-37.5%	$77.7M
Current Assets	$38.2M+3.1%	$37.0M+28.7%	$28.8M-18.5%	$35.3M+0.1%	$35.3M-49.2%	$69.5M
Cash & Equivalents	$10.7M-31.6%	$15.7M+74.4%	$9.0M-11.1%	$10.1M-23.9%	$13.3M-72.7%	$48.7M
Inventory	$3.4M-40.7%	$5.8M-1.6%	$5.9M+1.0%	$5.8M+42.6%	$4.1M+4.2%	$3.9M
Accounts Receivable	$8.1M-1.8%	$8.3M-23.9%	$10.9M+74.2%	$6.3M+5.9%	$5.9M+41.8%	$4.2M
Goodwill	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K
Total Liabilities	$20.2M-24.3%	$26.6M-13.8%	$30.9M-5.1%	$32.5M-29.3%	$46.0M+5.6%	$43.6M
Current Liabilities	$9.6M-32.0%	$14.1M-15.3%	$16.6M-6.0%	$17.7M-15.6%	$21.0M+63.9%	$12.8M
Long-Term Debt	$8.8M+4.2%	$8.5M+2.2%	$8.3M+9.8%	$7.6M-42.7%	$13.2M-37.1%	$20.9M
Total Equity	$37.0M+13.5%	$32.6M+53.1%	$21.3M+50.9%	$14.1M+456.4%	$2.5M-92.6%	$34.2M
Retained Earnings	-$403.0M-1.3%	-$397.7M-0.1%	-$397.2M-2.2%	-$388.8M-5.0%	-$370.1M-9.7%	-$337.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$57.4M+0.5%	$57.1M-0.6%	$57.5M+9.2%	$52.6M-2.5%	$54.0M-8.9%	$59.2M+3.7%	$57.1M+7.6%	$53.0M
Current Assets	$36.9M-3.2%	$38.2M+1.7%	$37.5M+18.7%	$31.6M-4.3%	$33.0M-10.8%	$37.0M+8.2%	$34.2M+15.0%	$29.8M
Cash & Equivalents	$9.6M-10.3%	$10.7M-21.3%	$13.6M+9.0%	$12.5M+9.6%	$11.4M-27.3%	$15.7M+26.9%	$12.3M+4.0%	$11.9M
Inventory	$3.1M-10.8%	$3.4M-13.6%	$4.0M-4.7%	$4.2M-17.5%	$5.0M-12.7%	$5.8M-1.9%	$5.9M+0.1%	$5.9M
Accounts Receivable	$8.8M+8.4%	$8.1M-2.2%	$8.3M+3.0%	$8.1M-16.4%	$9.7M+16.6%	$8.3M-6.7%	$8.9M-18.0%	$10.8M
Goodwill	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K0.0%	$921K
Total Liabilities	$21.6M+7.0%	$20.2M-1.5%	$20.5M-7.9%	$22.2M-1.0%	$22.4M-15.7%	$26.6M-4.7%	$27.9M-5.4%	$29.5M
Current Liabilities	$9.9M+3.0%	$9.6M0.0%	$9.6M-12.5%	$10.9M-2.3%	$11.2M-20.5%	$14.1M-0.6%	$14.2M-4.8%	$14.9M
Long-Term Debt	$8.2M-7.0%	$8.8M+1.0%	$8.7M+1.0%	$8.6M+1.0%	$8.6M+1.0%	$8.5M+1.1%	$8.4M+1.1%	$8.3M
Total Equity	$35.9M-3.0%	$37.0M-0.1%	$37.0M+21.7%	$30.4M-3.5%	$31.5M-3.3%	$32.6M+11.8%	$29.1M+24.0%	$23.5M
Retained Earnings	-$404.6M-0.4%	-$403.0M-0.1%	-$402.4M-0.4%	-$400.7M-0.4%	-$399.2M-0.4%	-$397.7M-0.2%	-$396.9M+0.4%	-$398.6M

RMTI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$659K-115.7%	$4.2M+144.6%	-$9.4M+44.4%	-$16.9M+49.5%	-$33.5M-13.1%	-$29.6M
Capital Expenditures	$542K-46.4%	$1.0M+256.0%	$284K	N/A	N/A	N/A
Free Cash Flow	-$1.2M-137.6%	$3.2M+132.9%	-$9.7M	N/A	N/A	N/A
Investing Cash Flow	-$8.5M-75.6%	-$4.9M-59.8%	-$3.0M-27.1%	-$2.4M-870.4%	$311K-90.3%	$3.2M
Financing Cash Flow	$4.3M-42.1%	$7.3M-35.2%	$11.3M-29.8%	$16.1M+841.2%	-$2.2M-103.4%	$63.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$167K-107.3%	$2.3M+275.3%	-$1.3M-170.9%	$1.8M+152.9%	-$3.5M-503.1%	$865K-79.8%	$4.3M+196.5%	$1.4M
Capital Expenditures	$425K+394.2%	$86K-62.4%	$229K+39.6%	$164K+160.3%	$63K-84.1%	$395K+106.8%	$191K-33.2%	$286K
Free Cash Flow	-$592K-126.8%	$2.2M+243.6%	-$1.5M-191.4%	$1.7M+147.3%	-$3.5M-855.3%	$470K-88.5%	$4.1M+253.3%	$1.2M
Investing Cash Flow	-$122K+97.0%	-$4.1M+4.1%	-$4.3M-4083.5%	-$103K-10200.0%	-$1K+99.7%	-$332K+94.6%	-$6.1M-456.0%	$1.7M
Financing Cash Flow	-$813K+23.2%	-$1.1M-115.7%	$6.7M+1137.5%	-$650K+17.0%	-$783K-128.0%	$2.8M+20.7%	$2.3M+12.0%	$2.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RMTI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	16.9%-0.3pp	17.2%+6.8pp	10.4%+4.8pp	5.6%+9.5pp	-3.9%-8.3pp	4.4%
Operating Margin	-6.8%-7.4pp	0.6%+8.6pp	-8.0%+15.1pp	-23.1%+25.9pp	-49.0%-3.3pp	-45.7%
Net Margin	-7.7%-7.2pp	-0.5%+9.6pp	-10.1%+15.6pp	-25.7%+27.1pp	-52.8%-3.1pp	-49.7%
Return on Equity	-14.4%-12.9pp	-1.5%+38.2pp	-39.6%+92.8pp	-132.4%+1156.5pp	-1288.9%-1198.5pp	-90.4%
Return on Assets	-9.3%-8.5pp	-0.8%+15.4pp	-16.2%+23.9pp	-40.1%+27.2pp	-67.3%-27.5pp	-39.7%
Current Ratio	3.98+1.4	2.63+0.9	1.73-0.3	2.00+0.3	1.68-3.7	5.43
Debt-to-Equity	0.24-0.0	0.26-0.1	0.39-0.1	0.54-4.7	5.20+4.6	0.61
FCF Margin	-1.7%-4.9pp	3.1%+14.7pp	-11.6%	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	16.7%-4.4pp	21.1%+6.9pp	14.3%-1.3pp	15.6%-0.5pp	16.1%+1.4pp	14.7%-7.3pp	22.0%+4.4pp	17.6%
Operating Margin	-8.5%-6.4pp	-2.2%+7.8pp	-10.0%-1.6pp	-8.4%-1.2pp	-7.2%-5.1pp	-2.1%-8.9pp	6.8%+4.9pp	2.0%
Net Margin	-9.3%-6.2pp	-3.0%+8.0pp	-11.0%-1.7pp	-9.3%-1.3pp	-8.0%-4.9pp	-3.1%-8.9pp	5.9%+4.5pp	1.3%
Return on Equity	-4.5%-3.0pp	-1.5%+3.2pp	-4.7%+0.2pp	-4.9%-0.1pp	-4.8%-2.5pp	-2.3%-8.0pp	5.7%+4.3pp	1.5%
Return on Assets	-2.8%-1.8pp	-1.0%+2.1pp	-3.0%-0.2pp	-2.8%-0.0pp	-2.8%-1.5pp	-1.3%-4.2pp	2.9%+2.3pp	0.7%
Current Ratio	3.74-0.2	3.98+0.1	3.92+1.0	2.89-0.1	2.95+0.3	2.63+0.2	2.41+0.4	2.00
Debt-to-Equity	0.230.0	0.240.0	0.24-0.0	0.28+0.0	0.27+0.0	0.26-0.0	0.29-0.1	0.35
FCF Margin	-3.4%-15.4pp	12.0%+21.7pp	-9.6%-20.1pp	10.4%+29.2pp	-18.8%-20.7pp	1.9%-12.5pp	14.4%+9.9pp	4.5%

Similar Companies

DURECT DRRX

$59.3M

Assertio Holdings Inc ASRT

$151.9M

Cumberland Pharmaceuticals Inc CPIX

$104.7M

Intercure Ltd. INCR

$56.6M

Cardiol Therapeu CRDL

$132.6M

Frequently Asked Questions

What is Rockwell Med Inc's annual revenue?

Rockwell Med Inc (RMTI) reported $69.3M in total revenue for fiscal year 2025. This represents a -31.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rockwell Med Inc's revenue growing?

Rockwell Med Inc (RMTI) revenue declined by 31.8% year-over-year, from $101.5M to $69.3M in fiscal year 2025.

Is Rockwell Med Inc profitable?

No, Rockwell Med Inc (RMTI) reported a net income of -$5.3M in fiscal year 2025, with a net profit margin of -7.7%.

What is Rockwell Med Inc's EBITDA?

Rockwell Med Inc (RMTI) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rockwell Med Inc have?

As of fiscal year 2025, Rockwell Med Inc (RMTI) had $10.7M in cash and equivalents against $8.8M in long-term debt.

What is Rockwell Med Inc's gross margin?

Rockwell Med Inc (RMTI) had a gross margin of 16.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Rockwell Med Inc's operating margin?

Rockwell Med Inc (RMTI) had an operating margin of -6.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Rockwell Med Inc's net profit margin?

Rockwell Med Inc (RMTI) had a net profit margin of -7.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Rockwell Med Inc's return on equity (ROE)?

Rockwell Med Inc (RMTI) has a return on equity of -14.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rockwell Med Inc's free cash flow?

Rockwell Med Inc (RMTI) generated -$1.2M in free cash flow during fiscal year 2025. This represents a -137.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rockwell Med Inc's operating cash flow?

Rockwell Med Inc (RMTI) generated -$659K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rockwell Med Inc's total assets?

Rockwell Med Inc (RMTI) had $57.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Rockwell Med Inc's capital expenditures?

Rockwell Med Inc (RMTI) invested $542K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Rockwell Med Inc have outstanding?

Rockwell Med Inc (RMTI) had 39M shares outstanding as of fiscal year 2025.

What is Rockwell Med Inc's current ratio?

Rockwell Med Inc (RMTI) had a current ratio of 3.98 as of fiscal year 2025, which is generally considered healthy.

What is Rockwell Med Inc's debt-to-equity ratio?

Rockwell Med Inc (RMTI) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rockwell Med Inc's return on assets (ROA)?

Rockwell Med Inc (RMTI) had a return on assets of -9.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rockwell Med Inc's cash runway?

Based on fiscal year 2025 data, Rockwell Med Inc (RMTI) had $10.7M in cash against an annual operating cash burn of $659K. This gives an estimated cash runway of approximately 195 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rockwell Med Inc's Altman Z-Score?

Rockwell Med Inc (RMTI) has an Altman Z-Score of -7.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rockwell Med Inc's Piotroski F-Score?

Rockwell Med Inc (RMTI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rockwell Med Inc's earnings high quality?

Rockwell Med Inc (RMTI) has an earnings quality ratio of 0.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rockwell Med Inc cover its interest payments?

Rockwell Med Inc (RMTI) has an interest coverage ratio of -4.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rockwell Med Inc?

Rockwell Med Inc (RMTI) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.